Novo-owned biotech continues progress

Earlier this year, Novo A/S invested a double-digit million euros sum in the promising German biotech and CRO Evotec. The company has gone from a net deficit to a net profit, while its revenue increased by one third in the first quarter. A Novo director is set to join the company's board of directors.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Get 14 days free trial access

Frontpage right now

Latest Top picks in English

Related articles